Immix Biopharma, Inc

67 articles about Immix Biopharma, Inc

• Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma

  10/2/2023

  Immix Biopharma Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) today announced the presentation of updated data from the ongoing Phase 1b/2 NEXICART-1 (NCT04720313) study of its novel, autologous, BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201.

• U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Amyloid Light Chain (AL) Amyloidosis

  9/21/2023

  Immix Biopharma, Inc., a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation designation for NXC-201 for the treatment of a life-threatening blood disorder, Amyloid Light Chain Amyloidosis.

• Immix Biopharma Subsidiary Nexcella Completes 2nd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site

  9/19/2023

  Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, today announced the successful completion of its 2nd CAR-T NXC-201 engineering batch at its U.S. manufacturing site.

• Nexcella, Immix Biopharma Subsidiary, to Present at the Bank of America 2023 Healthcare Trailblazers Private Company Conference

  9/7/2023

  Immix Biopharma, Inc. today announced that Nexcella NXC-201 clinical data will be presented by Ilya Rachman, MD, PhD, and Gabriel Morris at the Healthcare Trailblazers Private Company Conference Thursday, October 26, 2023. 

• Immix Biopharma Announces Dr. Suzanne Lentzsch, Director of the Multiple Myeloma and Amyloidosis Program at the College of Physicians and Surgeons of Columbia University and at NY Presbyterian Hospital in NY, Joins Scientific Advisory Board

  9/1/2023

  Immix Biopharma, Inc., a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, announced that effective , Dr. Suzanne Lentzsch has joined the Nexcella Scientific Advisory Board.

• U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Multiple Myeloma

  8/23/2023

  Immix Biopharma, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) designation for NXC-201 for the treatment of a life-threatening form of blood cancer, multiple myeloma.

• Immix Biopharma Announces Dr. Heather Landau, Memorial Sloan Kettering Cancer Center Amyloidosis Program Director, Joins Nexcella Scientific Advisory Board

  8/18/2023

  Dr. Landau joins the Nexcella Scientific Advisory Board with decades of hematology/oncology clinical trial experience at Memorial Sloan Kettering Cancer Center.

• Immix Biopharma Announces Additional NXC-201 AL Amyloidosis Clinical Data Accepted for Oral Presentation at the 20th International Myeloma Society Annual Meeting (September 27-30, Athens Greece)

  8/16/2023

  Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”) today announced that additional NXC-201 clinical data for relapsed/refractory AL Amyloidosis has been selected for oral presentation at the 20th International Myeloma Society Annual Meeting to be held in Athens, Greece, September 27-30, 2023.

• Immix Biopharma Subsidiary Nexcella Announces NXC-201 Multiple Myeloma Clinical Data Abstract Accepted for Presentation at the 20th International Myeloma Society Annual Meeting

  7/25/2023

  Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (“Nexcella”, “Company”, “We” or “Us”), today announced that updated NXC-201 relapsed/refractory multiple myeloma clinical data has been selected for presentation at the upcoming 20th International Myeloma Society Annual Meeting to be held in Athens, Greece, September 27-30, 2023.

• Immix Biopharma Reports 2nd Positive Interim Clinical Trial Data Readout in Relapsed/Refractory Metastatic Colorectal Cancer in Ongoing Phase 1b/2a IMX-110 IMMINENT-01 Clinical Trial

  7/17/2023

  Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) today announced its 2nd positive IMX-110 interim update from the Company’s ongoing Phase 1b/2a IMMINENT-01 (NCT05840835) study of IMX-110 in combination with BeiGene's anti-PD-1 antibody tislelizumab.

• Immix Biopharma Subsidiary Nexcella Completes Initial NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing SiteSupports planned expansion of its ongoing NEXICART-1 (NCT04720313) NXC-201 CAR-T clinical trial to the U.S.

  7/10/2023

  Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (“Nexcella”, “Company”, “We” or “Us”), today announced the completion of its initial CAR-T NXC-201 engineering batch at its U.S. manufacturing site.

• Immix Biopharma Subsidiary Nexcella Appoints Edward J. Borkowski, former Chief Financial Officer of Mylan N.V, to Board of Directors

  6/22/2023

  Nexcella, Inc., a subsidiary of Immix Biopharma, Inc., announced that effective today, Edward J. Borkowski, former Chief Financial Officer of Mylan N.V, has been appointed to the Company’s Board of Directors.

• Immix Biopharma Subsidiary Nexcella Appoints Jeffrey H. Cooper, former Chief Financial Officer of BioMarin, to Board of Directors

  6/20/2023

  Nexcella, Inc., a subsidiary of Immix Biopharma, Inc., announced that effective , Jeffrey H. Cooper, former Chief Financial Officer of BioMarin Pharmaceutical Inc., has been appointed to the Company’s Board of Directors.

• Immix Biopharma Subsidiary Nexcella Appoints Mary Sue Coleman, former Johnson & Johnson Independent Director, to Board of Directors

  6/16/2023

  Nexcella, Inc., a subsidiary of Immix Biopharma, Inc., announced that effective , Mary Sue Coleman, former Independent Director of Johnson & Johnson, has been appointed to the Company’s Board of Directors.

• Immix Biopharma Subsidiary Nexcella Appoints Henry McKinnell, Jr., former Chairman & CEO of Pfizer Inc., to Board of Directors

  6/12/2023

  Nexcella, Inc., a subsidiary of Immix Biopharma, Inc., announced that effective today, Henry A. McKinnell, Jr, Ph.D., former Chairman and Chief Executive Officer of Pfizer Inc., has been appointed to the Company’s Board of Directors.

• Immix Biopharma Subsidiary Nexcella Announces Commencement of NXC-201 Engineering Batches at its U.S. CAR-T Manufacturing Site

  5/26/2023

  Nexcella, Inc., a subsidiary of Immix Biopharma, Inc., announced the commencement of CAR-T NXC-201 Engineering Batches at its U.S. Manufacturing Site. These U.S. engineering batches will support the planned U.S. expansion of the Company’s ongoing Phase 1b/2a NEXICART-1 study of its novel BCMA-targeted chimeric antigen receptor T cell therapy NXC-201.

• Immix Biopharma Announces Positive NXC-201 Clinical Results at ASGCT: 100% Overall Response Rate in DARZALEX-Relapsed/Refractory AL Amyloidosis with Zero ICANs in Ongoing NEXICART-1 Phase 1b/2a Clinical Trial

  5/21/2023

  Immix Biopharma, Inc., announced updated AL Amyloidosis clinical data from its ongoing Phase 1b/2a NEXICART-1 study of its novel, autologous, BCMA-targeted chimeric antigen receptor T cell therapy NXC-201 for the treatment of patients with relapsed or refractory multiple myeloma and light chain amyloidosis.

• Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 26th Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT)

  5/4/2023

  Immix Biopharma, Inc. announced that updated NXC-201 clinical data has been selected for presentation at the upcoming 26th Annual Meeting of The American Society of Gene & Cell Therapy to be held in Los Angeles May 16-20, 2023.

• Nexcella, an Immix Biopharma subsidiary, announces poster presentation at the European Society for Blood and Marrow Transplantation 49th Annual Meeting

  4/4/2023

  Nexcella Inc., a subsidiary of Immix Biopharma, Inc. announced that updated NXC-201 clinical data has been selected to be presented at the upcoming 49th annual meeting of the European Society for Blood and Marrow Transplantation to be held in Paris, France, 23-26 April 2023.

• Nexcella Announces New Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in AL Amyloidosis Patients + Additional Positive Multiple Myeloma Safety Data Demonstrating NXC-201 Outpatient CAR-T Treatment Potential

  3/23/2023

  Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. announced that NXC-201 treatment continues to demonstrate 100% complete hematologic responses and 100% organ response rate – cardiac, renal, liver response – in a total of 8 AL amyloidosis patients.